EUVIMEDOpdag EUVIMED
MetaanalyseÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome

Giovanni Marasco iD, Marcello Maida iD, Cesare Cremon iD, Maria Raffaella Barbaro iD, Vincenzo Stanghellini, Giovanni Barbara iD

Alimentary Pharmacology & Therapeutics · 2023-07 · 58 (1) · 6-15

DOI: 10.1111/apt.17513 ↗

At a glance

Metaanalyse in Alimentary Pharmacology & Therapeutics, published online on 2023-04-10. Written by Giovanni Marasco and 5 co-authors. Institution: IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy. Major MEDLINE topics: Irritable Bowel Syndrome, Dyspepsia, COVID-19. Cited 51 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Università di Bologna, Fondazione del Monte di Bologna e Ravenna, Horizon 2020 Framework Programme.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

The burden of post‐COVID‐19 functional dyspepsia (FD) and irritable bowel syndrome (IBS) remains unclear. The aim of this meta‐analysis was to estimate the rate of post‐COVID‐19 FD and IBS.

Methods

MEDLINE, Scopus and Embase were searched through 17 December 2022. Studies reporting the incidence of FD and/or IBS in COVID‐19 survivors and controls (without COVID‐19), when available, according to the Rome criteria, were included. Estimated incidence with 95% confidence intervals (CI) was pooled. The odds ratio (OR) with 95% confidence intervals (CI) was pooled; heterogeneity was expressed as I 2 .

Results

Ten studies met the inclusion criteria and were included in the analysis. Overall, four studies including 1199 COVID‐19 patients were considered for FD. Post‐COVID‐19 FD was reported by 72 patients (4%, 95% CI: 3%–5% and I 2 0%). The pooled OR for FD development (three studies) in post‐COVID‐19 patients compared to controls was 8.07 (95% CI: 0.84–77.87, p = 0.071 and I 2 = 67.9%). Overall, 10 studies including 2763 COVID‐19 patients were considered for IBS. Post‐COVID‐19 IBS was reported by 195 patients (12%, 95% CI: 8%–16%, I 2 95.6% and Egger's p = 0.002 test). The pooled OR for IBS development (four studies) in COVID‐19 patients compared to controls was 6.27 (95% CI: 0.88–44.76, p = 0.067 and I 2 = 81.4%); considering only studies with a prospective COVID‐19 cohort (three studies), the pooled OR was 12.92 (95% CI: 3.58–46.60, p < 0.001 and I 2 = 0%).

Conclusions

COVID‐19 survivors were found to be at risk for IBS development compared to controls. No definitive data are available for FD.

Subjects

MeSH terms (MEDLINE)

Irritable Bowel SyndromeDyspepsiaCOVID-19HumansOdds Ratio

Author keywords

COVID-19DGBISARS-CoV-2functional dyspepsiairritable bowel syndromemeta-analysis

Authors and institutions

  • IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Science, University of Bologna, Bologna, Italy.
  • Gastroenterology and Endoscopy Unit, S. Elia - Raimondi Hospital, Caltanissetta, Italy.

ORCID profiles: Giovanni Marasco, Marcello Maida, Cesare Cremon, Maria Raffaella Barbaro, Giovanni Barbara

Funding

  • Università di Bologna
  • Fondazione del Monte di Bologna e Ravenna
  • Horizon 2020 Framework Programme

Cite

APA

Marasco, G., Maida, M., Cremon, C., Barbaro, M. R., Stanghellini, V., & Barbara, G. (2023). Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 58(1), 6-15. https://doi.org/10.1111/apt.17513

Vancouver

Marasco G, Maida M, Cremon C, Barbaro MR, Stanghellini V, Barbara G. Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2023;58(1):6-15. doi:10.1111/apt.17513

BibTeX
@article{Marasco2023,
  author = {Marasco, Giovanni and Maida, Marcello and Cremon, Cesare and Barbaro, Maria Raffaella and Stanghellini, Vincenzo and Barbara, Giovanni},
  title = {Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {58},
  number = {1},
  pages = {6--15},
  doi = {10.1111/apt.17513}
}
Start for free →